

Improvement of indirect enzyme-linked immunosorbent assay for detection of Japanese encephalitis virus antibodies in swine sera

Dong-Kun Yang^{1,*}, Ha-Hyun Kim¹, Hyun-Ye Jo¹, Seung Heon Lee¹, Sang-Ho Jang², Sang-Oh Lee², Sung-Suk Choi¹, In-Soo Cho¹

¹*Viral Disease Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Korea*

²*R&D Center, MEDIAN Diagnostics, Chuncheon 24399, Korea*

(Received: October 26, 2016; Revised: February 14, 2017; Accepted: February 23, 2017)

Abstract: Japanese encephalitis (JE) is an important zoonosis caused by the mosquito-transmitted JE virus (JEV), which is a causative agent of reproductive failure in pregnant sows. Detection of JEV antibodies in swine is performed by hemagglutination inhibition (HI), virus neutralization (VN), and the plaque reduction neutralization test (PRNT). The most stringent PRNT is the 90% endpoint PRNT (PRNT₉₀). These conventional assays are difficult to carry out in diagnostic laboratories with insufficient instruments or cell culture systems. An alternative assay that is easily conducted and time efficient is required. In this study, we improved the indirect enzyme-linked immunosorbent assay (I-ELISA) with clarified antigen for the detection of JEV antibodies. The I-ELISA results obtained from 175 swine serum samples were compared with HI, VN, and PRNT₉₀ results. The sensitivity of I-ELISA was 91.8%, 95.0%, and 94.7% compared with HI, VN, and PRNT₉₀ results, respectively. The specificity of I-ELISA was 92.2%, 94.7%, and 94.7% compared with HI, VN, and PRNT₉₀ results, respectively. Moreover, the I-ELISA results were significantly correlated with the HI ($r = 0.93$), VN ($r = 0.95$), and PRNT₉₀ ($r = 0.92$) results. These results suggest that the improved I-ELISA is useful for serosurveillance of JEV in swine.

Keywords: Japanese encephalitis virus, indirect enzyme-linked immunosorbent assay, surveillance, swine

Introduction

Japanese encephalitis (JE) is caused by JE virus (JEV), a member of the genus *Flavivirus* in the family *Flaviviridae*. The first case of JE in a human was reported in American soldiers stationed in South Korea in 1946 [16]. In the veterinary field, JEV was first isolated from piglets in Gyeonggi province of South Korea in 1969 [21]. JEV has been divided into five genotypes (G1–G5) based on the nucleotide sequence of its envelope gene [2, 5]. JEV G3 was the main genotype reported in most Asian countries until 1990 [6]. Since the 1990s, however, the predominant JEV genotype has shifted from G3 to G1 in Japan, Korea, and China [13, 14]. JEV G1 continues to be identified in *Culex* mosquitoes, swine blood, and cerebrospinal fluid from Korean patients, indicating that JEV G1 is the chief genotype circulating in Korea [2, 7, 14, 23].

Since the establishment of an extensive JE vaccination program for children in the mid-1960s, the number of human cases of JE has significantly decreased nationwide from 12,055 in 1961–1967 to 3,783 in 1968–1983 [9]. According to recent data obtained from the Korean Center for Disease

Control and Prevention, 122 cases of JE infection in humans were reported during 2001–2014 and 40 cases in 2015 [9]. In the veterinary field, only nine cases of JE in pigs have been reported since 2002 [4]. It is important to monitor the immune status of the pig population and implement appropriate measures, such as booster immunization of pigs in at-risk areas. The veterinary authorities in South Korea have conducted serosurveillance of immunity to JE in pig farms. A nationwide investigation on the prevalence of JEV antibodies is performed using the hemagglutination inhibition (HI) test in approximately 8,000 pig serum samples every year.

Several methods are used to detect JEV antibodies induced by vaccination or natural infection in pig serum samples. These include HI, virus neutralization (VN), the plaque reduction neutralization test (PRNT), enzyme-linked immunosorbent assay (ELISA), complement fixation, and the indirect immunofluorescence assay [1, 20]. HI has been considered the standard method to detect JEV antibodies. However, the complicated test procedures that need to use goose erythrocytes have limited the use of HI in the laboratory. VN and the PRNT have been considered the most reliable methods

*Corresponding author

Tel: +82-54-912-0785, Fax: +82-54-912-0812

E-mail: yangdk@korea.kr

for the evaluation of JEV vaccine efficacy. Although the PRNT can be useful for differential diagnoses in regions of West Nile virus infection, both VN and the PRNT require one week to obtain results [11]. ELISA is the preferable method to detect JEV antibodies, because it does not require live JEV but only a small amount of serum; additionally, the procedure is simple [18]. Several ELISA kits specific for the JEV antigen or antibody (antigen capture ELISA, immunoglobulin [Ig]M capture ELISA, and IgG ELISA) have been commercialized in the human field, but commercially available ELISA kits in the veterinary field, especially those for pigs, are rare [12, 15].

In a previous study, we reported the development and evaluation of indirect ELISA (I-ELISA) for the detection of JEV antibodies in swine [22]. In the present study, we improved the specificity and sensitivity of I-ELISA by applying highly purified JEV antigen, and the specificity and sensitivity were compared with those of HI, VN, and the PRNT.

Materials and Methods

Viruses and serum samples

Vero cells (African green monkey kidney cell line: ATCC CCL81) were maintained in alpha minimal essential medium (α -MEM; Gibco-BRL, USA) containing 5% (v/v) fetal bovine serum (Gibco-BRL), penicillin (100 IU/mL), streptomycin (100 μ g/mL), and amphotericin B (0.25 μ g/mL) at 37°C under 5% (v/v) CO₂. The KV1899 strain of JEV G1, which had undergone 120 serial passages in Vero cell culture, was used for I-ELISA, HI, and the 90% endpoint PRNT (PRNT₉₀). A K87 strain obtained from KCDC (NCCP No. 41305) was used for VN. In total, 175 swine serum samples collected from a slaughterhouse located in Gyeonggi province in 2015 were subjected to serological assays.

HI

Before conducting HI, all serum samples were inactivated in a water bath at 56°C for 30 min. HI was performed in 96-well U-bottom microplates using a slight modification of the standard method used to detect the JEV antibody in pig sera. Viral antigens for HI were prepared using a sucrose-acetone extraction method from the brains of 3-day-old mice infected with the Korean isolate of JEV strain KV1899. HI was performed as follows: 10 μ L pig serum and 50 μ L 4% bovine albumin were mixed with 40 μ L 25% kaolin (Sigma, USA) to remove nonspecific inhibitors, and the mixture was agitated by vibration every 5 min and incubated at room temperature for 30 min. After strong mixing, the kaolin was removed by centrifugation at 8,000 \times g for 5 min and the supernatant was transferred to a new tube. The resultant clear supernatant was mixed with 5 μ L packed goose erythrocytes to remove any natural agglutinins. After incubation at 37°C for 1 h, the goose erythrocytes were also removed as described above. The supernatant was then ready for HI (1/10 dilution). The treated serum samples (25 μ L) were diluted two-

fold from 1:10 to 1:20,480 in the U-bottom microplates and reacted with 8 HA units of JEV. After incubation of the plate sealed with vinyl tape at 37°C for 1 h, 50 μ L 0.33% goose erythrocytes were added to the microplates and incubated at 37°C for 30 min. To confirm test reliability, positive and negative JEV infection pig control sera were used in all HI tests. The HI titer was expressed as the reciprocal of the highest dilution of serum showing complete HI. An HI titer of 1:10 or higher was considered positive.

VN

VN was performed in 96-well microplates using Vero cells. Each serum sample, including the positive and negative controls, was evaluated in duplicate and serial two-fold dilutions. JEV (K87 strain; 100 TCID₅₀/50 μ L) was added to each well. After incubation at 37°C for 1 h, 0.1 mL Vero cell suspension (5.0×10^4 cells/mL) was added to each well. The microplates were incubated for 72 h in a humidified incubator under 5% (v/v) CO₂ at 37°C, and the virus-induced cytopathic effect was evaluated microscopically. Each titer was the reciprocal of the highest serum dilution that completely inhibited the cytopathic effect. Each serum sample was diluted from 1:2 to 1:256. A VN titer \geq 1:2 was considered positive.

PRNT₉₀

The PRNT₉₀ was performed using monolayers of Vero cells seeded at 1.0 to 5.0×10^4 /well of 24-well plates in α -MEM (Gibco-BRL). Cells were incubated for 2 days at 37°C. Test sera were heat-inactivated at 56°C for 30 min. The same volume (200 μ L) of the test sera in two-fold dilutions (from 1:10 to 1:320) and KV1899 virus diluent (200 pfu/mL) were mixed and incubated for 60 min at 37°C. The virus-serum mixture was inoculated (0.1 mL/well) and absorbed for 1 h at 37°C, at which point the inoculums were removed. The emptied wells were replaced with 0.5 mL 1.0% low-melting-point agarose in α -MEM containing 2.5% heat-inactivated fetal bovine serum. The agarose overlay was allowed to harden for 1 h at room temperature, and the plates were incubated upside down to minimize water condensation in the wells in a CO₂ incubator at 37°C for 48 h to allow virus plaques to develop. The second overlay containing 1.0% low-melting-point agarose in α -MEM with 0.1% neutral red was added to all wells, and the plates were incubated upside down in a CO₂ incubator at 37°C for 48 h to allow maximal staining of the cells. Plaques in the serum-free control wells were counted after 2 days of the second overlay by gross examination. The antibody titer in the serum was calculated as the antibody count that reduced the number of plaques by 90% of the control without serum. A PRNT₉₀ titer \geq 1:20 was considered positive.

I-ELISA

JEV was propagated in Vero cells, and to remove cell debris, approximately 1 L viral suspension was harvested and

filtered through a membrane filter (0.2 μm pore size) [21]. The clarified antigen was concentrated using the Bio-max 100 of the Pellicon XL device (Millipore, USA). The concentrated JEV antigen was purified by discontinuous sucrose gradient centrifugation in an ultracentrifuge. For this procedure, 10 to 50% sucrose solution in GTNE buffer (200 mM glycine, 100 mM Tris-Cl, 100 mM NaCl, and 1 mM EDTA; pH 7.6) was prepared. The JEV antigen was layered on top of the 20% sucrose solution and centrifuged at $100,000 \times g$ for 3 h in a SW 41 Ti rotor (Beckman Coulter, USA). The band in the sucrose gradient representing the virus was collected and dialyzed with phosphate buffered saline (PBS) (pH 7.2) to eliminate the residual sucrose overnight at 4°C. The virus protein concentration was determined using a bicinchoninic protein assay kit (Pierce, USA) and characterized by western blot analysis to verify the presence of antigenic proteins associated with purified JEV using an antibody specific to the JEV E protein.

Optimal coating antigen concentrations and dilutions of serum, conjugate, and substrate were determined by a check-board titration test. The JEV protein was used at concentrations of 1, 2, 3, and 4 $\mu\text{g}/\text{mL}$, and the serum samples were tested at dilutions of 1:10 to 1,280. The optimal antigen and conjugate concentrations and the serum dilution used for I-ELISA, each with a 450 nm absorbance value of 1.3, were determined. Each 100 μL serum in dilution buffer were placed in a 96-well microplate (Maxisorp; NUNC, Denmark) coated with JEV antigen. After incubation at 37°C for 1 h, the plate was washed with PBS containing 0.05% Tween 20 and incubated with 100 μL anti-swine IgG HRP conjugate (KPL, USA) for 1 h at 37°C. After washing, 100 μL 3,3',5,5'-tetra methylbenzidine substrate solution were added to all wells of the microplate, which was then incubated for 10 min at room temperature. Fifty microliters of 0.5 M sulfuric acid were added to stop the reaction. The absorbance at 450 nm was measured in a spectrophotometer (Sunrise ELISA reader; Tecan, Switzerland). Serum samples were evaluated as posi-

tive if the absorbance value was higher than the cutoff value (0.25). The specificity, sensitivity, and accuracy were calculated using the following formula: sensitivity (%) = (number of positives in both tests / total number of positives in the reference test) \times 100; specificity (%) = (number of negatives in both tests / total number of negatives in the reference test) \times 100; and accuracy (%) = (real number of both positives and negatives / total number of samples) \times 100.

Statistical analysis

Linear regression analysis (least-squares method) was used to determine the correlations between the ELISA data and the HI, VN, or PRNT₉₀ data. The correlation coefficient (*r* value) was computed using SigmaPlot statistical software (ver. 10.0 for Windows; SYSTAT, USA). A *P* value < 0.05 was considered to be statistically significant.

Results

Determination of the JEV antibody titer

Four antibody detection assays (HI, VN, PRNT₉₀, and I-ELISA) were carried to detect JEV antibodies out in 175 sow serum samples. Table 1 shows that 77, 75, 75, and 79 serum samples were positive in HI titers of 1:10 to 1:2,560, VN titers of 1:2 to 1:256, PRNT₉₀ titers of 1:20 to 1:640, and I-ELISA absorbance values > 0.25, respectively. The numbers of JEV-negative serum samples were 98, 100, 100, and 96 with the HI, VN, PRNT₉₀, and I-ELISA, respectively.

Optimization of I-ELISA

JEV antigen (15 mg) was harvested from several purifications, and the major protein from the purified JEV antigen was identified by western blotting as a 54 kDa band using a monoclonal antibody to the JEV E protein (Fig. 1). We determined the optimal antigen concentration (2 $\mu\text{g}/\text{mL}$), conjugate concentration (10 ng/mL), and serum dilution (1:100). The most suitable blocking and serum dilution buffer was

Table 1. Determination of the sensitivity, specificity, and accuracy of the indirect enzyme-linked immunosorbent assay (I-ELISA) for the detection of Japanese encephalitis virus (JEV) antibodies in comparison with those of hemagglutination inhibition (HI), virus neutralization (VN), and the 90% endpoint plaque reduction neutralization test (PRNT₉₀)

	Number of samples with HI		Number of samples with VN		Number of samples with the PRNT ₉₀	
	Positive	Negative	Positive	Negative	Positive	Negative
ELISA						
Positive (n = 79)	71	8	74	5	74	5
Negative (n = 96)	6	90	1	95	1	95
Sum (n = 175)	77	98	75	100	75	100
Sensitivity*	92.2%		98.7%		98.7%	
Specificity†	91.8%		95.0%		95.0%	
Accuracy‡	92.0%		94.8%		94.8%	

*Sensitivity (%) = (number of positive results in both tests / total number of positive results in the reference test) \times 100. †Specificity (%) = (number of negative results in both tests / total number of negative results in the reference test) \times 100. ‡Accuracy (%) = (actual number of both positive and negative results / total number of samples) \times 100.




Fig. 1. Identification of the JEV envelope protein by western blotting using monoclonal antibodies specific to JEV. The molecular weight was 54 kDa. M, protein ladder; Lane 1, purified JEV antigen.




Fig. 2. Comparison of the abilities of the HI titer and I-ELISA to detect JEV antibodies in 175 swine serum samples. The correlation between HI and I-ELISA is indicated by the linear regression line and *r*-value.

1% casein in PBS (data not shown). In addition, an absorbance value of 0.25 was set as the threshold (cutoff value). Therefore, an absorbance value of >0.25 in I-ELISA was considered positive. Based on these results, the commercial I-ELISA kit was prepared, and evaluated with 175 swine serum samples.

Comparison of serological assays

The absorbance value from I-ELISA was compared with titers of the HI, VN, or PRNT₉₀ using 175 serum samples to evaluate its diagnostic reliability. As shown in Figures 2–4, correlations between I-ELISA and HI, between I-ELISA and VN, and between I-ELISA and PRNT₉₀ were indicated by regression lines and correlation coefficients (*r*). The *r*-values for HI, VN, and the PRNT₉₀ were 0.93 (*p* < 0.05), 0.95 (*p* < 0.05), and 0.92 (*p* < 0.05), respectively. The diagnostic sensi-




Fig. 3. Comparison of the abilities of the VN titer and I-ELISA to detect JEV antibodies in 175 swine serum samples. The correlation between VN and I-ELISA is indicated by the linear regression line and *r*-value.




Fig. 4. Comparison of the abilities of the PRNT₉₀ titer and I-ELISA to detect JEV antibodies in 175 swine serum samples. The correlation between PRNT₉₀ and I-ELISA is indicated by the linear regression line and *r*-value.

tivity, specificity, and accuracy of I-ELISA were calculated from the JEV positive/negative sera measured by standard diagnostic assays such as HI, VN, and the PRNT₉₀. Table 1 shows that 71 or 74 serum samples were positive but 90 or 95 serum samples were negative according to a traditional assay, which represented 92.0% to 94.8% accuracy in the total samples. In contrast, the four tests yielded different results for 6 to 14 serum samples. Among these test results, one or six that were positive according to traditional standard assays was negative by I-ELISA, indicating specificities of 91.8%, 95.0%, and 95.0% for I-ELISA compared with HI, VN, and the PRNT₉₀, respectively. The five or eight serum samples that were negative by the three assays were positive by I-ELISA, indicating sensitivities of 92.2%, 98.7%, and 98.7% for I-ELISA compared with HI, VN, and the PRNT₉₀, respectively. In Table 2, the sensitivity, specificity, and accuracy among HI, VN, and the PRNT₉₀ were calculated using JEV positive/negative sera. The sensitivity, specificity, and accuracy of HI were 94.7%, 93.0%, and 93.7%, respectively, with VN and the PRNT₉₀. The number of JEV positive/nega-

Table 2. Comparison among HI, VN, and the PRNT₉₀ for the detection of JEV antibodies in swine sera

	Number of samples with VN		Number of samples with the PRNT ₉₀	
	Positive	Negative	Positive	Negative
HI				
Positive (n= 78)	71	7	71	7
Negative (n = 97)	4	93	4	93
Sum (n = 175)	75	100	75	100
Sensitivity*		94.7%		94.7%
Specificity†		93.0%		93.0%
Accuracy‡		93.7%		93.7%

*Sensitivity (%) = (number of positive results in both tests / total number of positive results in the reference test) × 100. †Specificity (%) = (number of negative results in both tests / total number of negative results in the reference test) × 100. ‡Accuracy (%) = (real number of both positive and negative results / total number of samples) × 100.

tive serum samples was equal between VN and the PRNT₉₀, indicating that both assays are involved in virus neutralization.

Discussion

JEV infection in humans can be prevented by vaccination, a reduction in mosquito numbers, and immunization of pigs [3]. Previous studies have shown that pigs amplify JEV and that sows infected with JEV develop fever and experience reproductive failure (*e.g.*, abortion) [10]. Because vaccination failure or missed vaccination can result in the development of JE in humans and pigs and can provide an opportunity for pigs to amplify the virus, preventive measures such as issuing warnings and performing revaccination have been implemented in association with seromonitoring of the JEV antibody in South Korea. Serological surveys of JEV are useful to determine the infection rate in pigs and the JEV antibody level in vaccinated animals. Although HI has been used as a serological method, regional veterinary institutes have begun replacing HI with ELISA, which is suitable for large numbers of serum samples and is simple and rapid. For this reason, we focused on improving I-ELISA as an alternative to HI in pigs and compared it with HI, VN, and the PRNT₉₀.

Because of the shift in the predominant JEV genotype from G3 to G1 in South Korea in the 1990s [14], the JEV G1 KV1899 strain was selected as the antigen for evaluation by I-ELISA, HI, and the PRNT₉₀. The JEV G3 K87 strain has been routinely used for VN in our laboratory. One of the most important factors affecting the sensitivity and specificity of ELISA is the use of purified antigen [17]. In our previous study, I-ELISA microplates were coated with JEV antigen, which was purified by PEG-8000 precipitation and sucrose gradient centrifugation [22]. To improve both the sensitivity and specificity, an antigen purified by filtration using the Pellicon XL Ultrafiltration Module Bio-max 100 kDa and discontinuous sucrose ultracentrifugation were used for the I-ELISA. These processes facilitate large-scale production of

whole JEV antigens by biologic companies.

The sensitivity, specificity, and accuracy of the new I-ELISA as well as their correlations with those of HI, VN, and the PRNT₉₀ were determined using 175 pig serum samples. The sensitivity of the I-ELISA compared with HI (92.2%) was slightly lower than that in previous results (94.3%), but the sensitivity compared with VN (98.7%) was higher (93.7%) [22]. Shimoda *et al.* [18] reported that the specificity of ELISA is the first priority to avoid false-positive reactions when developing IgG ELISAs. Compared with previous results regarding the specificity of I-ELISA compared with HI (81.4%) and VN (80.9%), the specificity of the new I-ELISA compared with both HI (91.8%) and VN (95.0%) was significantly improved. Our results also showed that the absorbance result of the I-ELISA was significantly correlated with those of the HI titer ($r = 0.93$), VN titer ($r = 0.95$), and PRNT₉₀ ($r = 0.92$). Moreover, these I-ELISA correlations are consistent with the results of previous studies that used rapid ELISA for detection of JEV antibodies in human and swine sera [8, 19], suggesting that the new I-ELISA is suitable for serosurveillance of JEV in swine. Further studies using other types of ELISA such as an IgM-capture or blocking ELISA are needed for the assessment of recent JEV infections in pigs or anti-JEV IgG from many susceptible animals, including horses.

In conclusion, we showed that the improved I-ELISA had a significant correlation with three serological tests in terms of the detection of JEV antibodies in pig serum samples, indicating that this new I-ELISA assay can be used as a fairly simple and efficient tool for examining a large number of serum samples at once.

Acknowledgments

This work was supported financially by a grant (N1543083-2014-18-01) from the Animal, and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs, Republic of Korea.

References

1. **Cha GW, Cho JE, Ju YR, Hong YJ, Han MG, Lee WJ, Choi EY, Jeong YE.** Comparison of four serological tests for detecting antibodies to Japanese encephalitis virus after vaccination in children. *Osong Public Health Res Perspect* 2014, **5**, 286-291.
2. **Chen WR, Tesh RB, Rico-Hesse R.** Genetic variation of Japanese encephalitis virus in nature. *J Gen Virol* 1990, **71**, 2915-2922.
3. **Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X.** Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. *Bull World Health Organ* 2003, **81**, 334-342.
4. **Forman S, Hungerford N, Yamakawa M, Yanase T, Tsai HJ, Joo YS, Yang DK, Nha JJ.** Climate change impacts and risks for animal health in Asia. *Rev Sci Tech* 2008, **27**, 581-597.
5. **Hasegawa H, Yoshida M, Fujita S, Kobayashi Y.** Comparison of structural proteins among antigenically different Japanese encephalitis virus strains. *Vaccine* 1994, **12**, 841-844.
6. **Kang BK, Hwang JM, Moon H, Han SY, Kim JM, Yang DK, Park BK, Song D.** Comparison of the antigenic relationship between Japanese encephalitis virus genotypes 1 and 3. *Clin Exp Vaccine Res* 2016, **5**, 26-30.
7. **Kim HC, Takhampunya R, Tippayachai B, Chong ST, Park JY, Kim MS, Seo HJ, Yeh JY, Lee WJ, Lee DK, Klein TA.** Japanese encephalitis virus in culicine mosquitoes (Diptera: Culicidae) of the republic of Korea, 2008-2010. *Mil Med* 2015, **180**, 158-167.
8. **Konishi E, Yamaoka M.** Rapid enzyme-linked immunosorbent assay of whole blood for detection of antibodies to Japanese encephalitis virus. *J Virol Methods* 1983, **7**, 21-28.
9. **Lee EJ, Cha GW, Ju YR, Han MG, Lee WJ, Jeong YE.** Prevalence of neutralizing antibodies to Japanese encephalitis virus among high-risk age groups in South Korea, 2010. *PLoS One* 2016, **11**, e0147841.
10. **Lindahl J, Boqvist S, Ståhl K, Thu HT, Magnusson U.** Reproductive performance in sows in relation to Japanese encephalitis virus seropositivity in an endemic area. *Trop Anim Health Prod* 2012, **44**, 239-245.
11. **Mansfield KL, Horton DL, Johnson N, Li L, Barrett ADT, Smith DJ, Galbraith SE, Solomon T, Fooks AR.** Flavivirus-induced antibody cross-reactivity. *J Gen Virol* 2011, **92**, 2821-2829.
12. **Mei L, Wu P, Ye J, Gao G, Shao L, Huang S, Li Y, Yang X, Chen H, Cao S.** Development and application of an antigen capture ELISA assay for diagnosis of Japanese encephalitis virus in swine, human and mosquito. *Virol J* 2012, **9**, 4.
13. **Morita K, Nabeshima T, Buerano CC.** Japanese encephalitis. *Rev Sci Tech* 2015, **34**, 441-452.
14. **Nah JJ, Yang DK, Kim HH, Song JY.** The present and future of veterinary vaccines for Japanese encephalitis in Korea. *Clin Exp Vaccine Res* 2015, **4**, 130-136.
15. **Ravi V, Desai A, Balaji M, Apte MP, Lakshman L, Subbakrishna DK, Sridharan G, Dhole TN, Ravikumar BV.** Development and evaluation of a rapid IgM capture ELISA (JEV-Chex) for the diagnosis of Japanese encephalitis. *J Clin Virol* 2006, **35**, 429-434.
16. **Sabin AB, Schlesinger RW, Ginder DR, Matsumoto M.** Japanese B encephalitis in American soldiers in Korea. *Am J Hyg* 1947, **46**, 356-375.
17. **Schrijver RS, Kramps JA.** Critical factors affecting the diagnostic reliability of enzyme-linked immunosorbent assay formats. *Rev Sci Tech* 1998, **17**, 550-561.
18. **Shimoda H, Inthong N, Noguchi K, Terada Y, Nagao Y, Shimojima M, Takasaki T, Rerkamnuaychoke W, Maeda K.** Development and application of an indirect enzyme-linked immunosorbent assay for serological survey of Japanese encephalitis virus infection in dogs. *J Virol Methods* 2013, **187**, 85-89.
19. **Xinglin J, Huanchun C, Xiang W, Changming Q.** Quantitative and qualitative study of enzyme-linked immunosorbent assay to detect IgG against Japanese encephalitis virus in swine sera. *Vet Res Commun* 2005, **29**, 159-169.
20. **Yamamoto A, Nakayama M, Tashiro M, Ogawa T, Kurane I.** Hydroxyapatite-coated nylon beads as a new reagent to develop a particle agglutination assay system for detecting Japanese encephalitis virus-specific human antibodies. *J Clin Virol* 2000, **19**, 195-204.
21. **Yang DK, Kim BH, Kweon CH, Kwon JH, Lim SI, Han HR.** Biophysical characterization of Japanese encephalitis virus (KV1899) isolated from pigs in Korea. *J Vet Sci* 2004, **5**, 125-130.
22. **Yang DK, Kim BH, Lim SI, Kwon JH, Lee KW, Choi CU, Kweon CH.** Development and evaluation of indirect ELISA for the detection of antibodies against Japanese encephalitis virus in swine. *J Vet Sci* 2006, **7**, 271-275.
23. **Yun SM, Cho JE, Ju YR, Kim SY, Ryou J, Han MG, Choi WY, Jeong YE.** Molecular epidemiology of Japanese encephalitis virus circulating in South Korea, 1983-2005. *Virol J* 2010, **7**, 127.